Myocardial Infarction - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 338 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Infarction - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H1 2015’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Myocardial Infarction Overview 11
Therapeutics Development 12
Pipeline Products for Myocardial Infarction - Overview 12
Pipeline Products for Myocardial Infarction - Comparative Analysis 13
Myocardial Infarction - Therapeutics under Development by Companies 14
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 20
Myocardial Infarction - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Myocardial Infarction - Products under Development by Companies 26
Myocardial Infarction - Products under Investigation by Universities/Institutes 32
Myocardial Infarction - Companies Involved in Therapeutics Development 34
A. Menarini Industrie Farmaceutiche Riunite Srl 34
Alligator Bioscience AB 35
Amarantus Bioscience Holdings, Inc. 36
Angion Biomedica Corp. 37
Aprogen, Inc. 38
APT Therapeutics, Inc. 39
AstraZeneca PLC 40
Athersys, Inc. 41
Bayer AG 42
Bharat Biotech International Limited 43
BioLineRx, Ltd. 44
Biscayne Pharmaceuticals, Inc. 45
Cardio3 BioSciences SA 46
Cellmid Limited 47
CellProthera 48
Compugen Ltd. 49
CSL Limited 50
FibroGen, Inc. 51
Fina Biotech 52
Genextra S.p.a. 53
GlaxoSmithKline plc 54
GliaMed, Inc. 55
Hadasit Medical Research Services & Development Ltd 56
Human Stem Cells Institute 57
HUYA Bioscience International, LLC 58
Immune Pharmaceuticals, Ltd. 59
Inbiopro Solutions Pvt. Ltd. 60
Juventas Therapeutics, Inc. 61
Laboratoires Pierre Fabre SA 62
Lacer, S.A. 63
Lee's Pharmaceutical Holdings Limited 64
LegoChem Biosciences, Inc 65
LG Life Sciences, Ltd. 66
Ligand Pharmaceuticals, Inc. 67
Medestea Research & Production S.p.A. 68
Merck & Co., Inc. 69
Mesoblast Limited 70
miRagen Therapeutics, Inc. 71
NeoStem, Inc. 72
NeuroVive Pharmaceutical AB 73
Omeros Corporation 74
Omni Bio Pharmaceutical Inc. 75
Pluristem Therapeutics Inc. 76
Polyphor Ltd. 77
Quantum Genomics SA 78
Recardio GmbH 79
Remedy Pharmaceuticals, Inc. 80
Serodus ASA 81
STELIS Biopharma Pvt. Ltd. 82
Stemedica Cell Technologies, Inc. 83
Stempeutics Research Private Limited 84
TaiGen Biotechnology Co., Ltd. 85
Targazyme, Inc. 86
Vicore Pharma AB 87
Zydus Cadila Healthcare Limited 88
Myocardial Infarction - Therapeutics Assessment 89
Assessment by Monotherapy Products 89
Assessment by Target 90
Assessment by Mechanism of Action 94
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 101
ADC-1004 - Drug Profile 101
Alpha-1 Antitrypsin - Drug Profile 102
amediplase - Drug Profile 104
AMR-001 - Drug Profile 105
AMRS-001 - Drug Profile 107
ANG-4011 - Drug Profile 109
AP-102 - Drug Profile 110
APT-102 - Drug Profile 111
Biglycan Therapy for Cardiovascular Diseases - Drug Profile 113
Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction - Drug Profile 114
Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 115
BIS-5409 - Drug Profile 116
BL-7060 - Drug Profile 117
Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases - Drug Profile 119
BQ-123 - Drug Profile 121
burixafor - Drug Profile 123
C-21 - Drug Profile 125
C3BSGQR-3 - Drug Profile 127
C3BSGQR-4 - Drug Profile 128
CAP-1001 - Drug Profile 129
CAP-1002 - Drug Profile 130
cenderitide - Drug Profile 132
CGEN-856 - Drug Profile 134
CGEN-856S - Drug Profile 135
CGEN-857 - Drug Profile 137
CIGB-500 - Drug Profile 138
clopidogrel bisulfate - Drug Profile 139
CM-1 - Drug Profile 140
CMK-103 - Drug Profile 142
Cryocell - Drug Profile 143
CSL-112 - Drug Profile 144
CTX-101 - Drug Profile 145
CTX-201 - Drug Profile 146
Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile 147
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 148
Ephrin A-1 - Drug Profile 149
F-573 - Drug Profile 150
Fc-Alpha-1 Antitrypsin - Drug Profile 151
FcAAT-2 - Drug Profile 152
FcAAT-3 - Drug Profile 153
FG-6874 - Drug Profile 154
Gemacell - Drug Profile 155
Gene Therapy for Acute Myocardial Infarction - Drug Profile 156
glyburide - Drug Profile 157
GM-1485 - Drug Profile 159
HBI-3802 - Drug Profile 161
HYPER-IL-6 - Drug Profile 162
IBPB-005ET - Drug Profile 163
ICG-001 - Drug Profile 164
JI-38 - Drug Profile 165
JVS-100 - Drug Profile 166
JVS-200 - Drug Profile 168
LA-8045 - Drug Profile 169
LC-280126 - Drug Profile 170
losmapimod - Drug Profile 172
Mesenchymal Stem Cells - Drug Profile 174
MGN-1374 - Drug Profile 176
MGN-6114 - Drug Profile 177
Monoclonal Antibody Conjugates to Target Mannose Receptor for Myocardial Infarction - Drug Profile 178
Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease - Drug Profile 179
MPC-150IM - Drug Profile 180
MTP-131 - Drug Profile 182
MultiStem - Drug Profile 184
NL-005 - Drug Profile 187
NVP-019 - Drug Profile 188
Oligonucleotide for Oncology and Cardiovascular - Drug Profile 189
Oligonucleotides for Cardiometabolic Diseases and Renal diseases - Drug Profile 190
OMS-721 - Drug Profile 191
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 193
POL-6326 - Drug Profile 194
Polyglactin 370 for Acute Myocardial Infarction - Drug Profile 196
ProtheraCytes - Drug Profile 197
QGC-101 - Drug Profile 199
REC-01 - Drug Profile 200
Recombinant Protein for Myocardial Infarction - Drug Profile 201
Recombinant Protein to Agonize IGF-1R for Myocardial Infarction - Drug Profile 202
remestemcel-L - Drug Profile 203
rivaroxaban - Drug Profile 206
RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 211
RNAi Oligonucleotide for Myocardial Infarction - Drug Profile 212
SBL-004 - Drug Profile 213
SER-130 - Drug Profile 214
Small Molecule for Myocardial Infarction - Drug Profile 215
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 216
Small Molecules for Myocardial Infarction and Inflammation - Drug Profile 217
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction - Drug Profile 218
Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 219
Small Molecules to Inhibit mPTP for Cardiovascular and Neurodegenerative Diseases - Drug Profile 220
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 221
Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders - Drug Profile 222
Stem Cell Therapy for Blood and Cardiovascular Diseases - Drug Profile 223
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 224
Stem Cell Therapy for Myocardial Infarction - Drug Profile 226
Stem Cell Therapy for Myocardial Infarction - Drug Profile 228
Stem Cells for Acute Myocardial Infarction - Drug Profile 229
Stempeucel - Drug Profile 230
Synthetic Peptide for Cardiovascular Diseases - Drug Profile 233
THR-100 - Drug Profile 234
ticagrelor - Drug Profile 236
TZ-101 - Drug Profile 240
VN-100 - Drug Profile 242
ZK-001 - Drug Profile 243
Myocardial Infarction - Recent Pipeline Updates 245
Myocardial Infarction - Dormant Projects 312
Myocardial Infarction - Discontinued Products 318
Myocardial Infarction - Product Development Milestones 319
Featured News & Press Releases 319
Appendix 330
Methodology 330
Coverage 330
Secondary Research 330
Primary Research 330
Expert Panel Validation 330
Contact Us 330
Disclaimer 331

List of Tables

Number of Products under Development for Myocardial Infarction, H1 2015 19
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 22
Number of Products under Development by Companies, H1 2015 (Contd..1) 23
Number of Products under Development by Companies, H1 2015 (Contd..2) 24
Number of Products under Development by Companies, H1 2015 (Contd..3) 25
Number of Products under Development by Companies, H1 2015 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2015 28
Comparative Analysis by Late Stage Development, H1 2015 29
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Development, H1 2015 31
Comparative Analysis by Unknown Stage Development, H1 2015 32
Products under Development by Companies, H1 2015 33
Products under Development by Companies, H1 2015 (Contd..1) 34
Products under Development by Companies, H1 2015 (Contd..2) 35
Products under Development by Companies, H1 2015 (Contd..3) 36
Products under Development by Companies, H1 2015 (Contd..4) 37
Products under Development by Companies, H1 2015 (Contd..5) 38
Products under Investigation by Universities/Institutes, H1 2015 39
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 40
Myocardial Infarction - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 41
Myocardial Infarction - Pipeline by Alligator Bioscience AB, H1 2015 42
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 43
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2015 44
Myocardial Infarction - Pipeline by Aprogen, Inc., H1 2015 45
Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H1 2015 46
Myocardial Infarction - Pipeline by AstraZeneca PLC, H1 2015 47
Myocardial Infarction - Pipeline by Athersys, Inc., H1 2015 48
Myocardial Infarction - Pipeline by Bayer AG, H1 2015 49
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2015 50
Myocardial Infarction - Pipeline by BioLineRx, Ltd., H1 2015 51
Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 52
Myocardial Infarction - Pipeline by Cardio3 BioSciences SA, H1 2015 53
Myocardial Infarction - Pipeline by Cellmid Limited, H1 2015 54
Myocardial Infarction - Pipeline by CellProthera, H1 2015 55
Myocardial Infarction - Pipeline by Compugen Ltd., H1 2015 56
Myocardial Infarction - Pipeline by CSL Limited, H1 2015 57
Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2015 58
Myocardial Infarction - Pipeline by Fina Biotech, H1 2015 59
Myocardial Infarction - Pipeline by Genextra S.p.a., H1 2015 60
Myocardial Infarction - Pipeline by GlaxoSmithKline plc, H1 2015 61
Myocardial Infarction - Pipeline by GliaMed, Inc., H1 2015 62
Myocardial Infarction - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 63
Myocardial Infarction - Pipeline by Human Stem Cells Institute, H1 2015 64
Myocardial Infarction - Pipeline by HUYA Bioscience International, LLC, H1 2015 65
Myocardial Infarction - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 66
Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 67
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2015 68
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2015 69
Myocardial Infarction - Pipeline by Lacer, S.A., H1 2015 70
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 71
Myocardial Infarction - Pipeline by LegoChem Biosciences, Inc, H1 2015 72
Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H1 2015 73
Myocardial Infarction - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 74
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2015 75
Myocardial Infarction - Pipeline by Merck & Co., Inc., H1 2015 76
Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2015 77
Myocardial Infarction - Pipeline by miRagen Therapeutics, Inc., H1 2015 78
Myocardial Infarction - Pipeline by NeoStem, Inc., H1 2015 79
Myocardial Infarction - Pipeline by NeuroVive Pharmaceutical AB, H1 2015 80
Myocardial Infarction - Pipeline by Omeros Corporation, H1 2015 81
Myocardial Infarction - Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 82
Myocardial Infarction - Pipeline by Pluristem Therapeutics Inc., H1 2015 83
Myocardial Infarction - Pipeline by Polyphor Ltd., H1 2015 84
Myocardial Infarction - Pipeline by Quantum Genomics SA, H1 2015 85
Myocardial Infarction - Pipeline by Recardio GmbH, H1 2015 86
Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 87
Myocardial Infarction - Pipeline by Serodus ASA, H1 2015 88
Myocardial Infarction - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2015 89
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2015 90
Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2015 91
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 92
Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2015 93
Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2015 94
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 95
Assessment by Monotherapy Products, H1 2015 96
Number of Products by Stage and Target, H1 2015 98
Number of Products by Stage and Mechanism of Action, H1 2015 102
Number of Products by Stage and Route of Administration, H1 2015 105
Number of Products by Stage and Molecule Type, H1 2015 107
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2015 252
Myocardial Infarction - Dormant Projects, H1 2015 319
Myocardial Infarction - Dormant Projects (Contd..1), H1 2015 320
Myocardial Infarction - Dormant Projects (Contd..2), H1 2015 321
Myocardial Infarction - Dormant Projects (Contd..3), H1 2015 322
Myocardial Infarction - Dormant Projects (Contd..4), H1 2015 323
Myocardial Infarction - Dormant Projects (Contd..5), H1 2015 324
Myocardial Infarction - Discontinued Products, H1 2015 325